CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
用于肿瘤治疗的溶瘤病毒研发
英文原题：Development of oncolytic viruses for cancer therapy.
查看英文原题
Development of oncolytic viruses for cancer therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
溶瘤病毒治疗利用具有复制能力的病毒杀伤癌细胞。溶瘤病毒可选择性地在癌细胞中复制，从而直接裂解细胞并诱导抗癌免疫反应。与其他抗癌疗法类似，溶瘤病毒治疗也面临若干限制，例如病毒递送至靶部位、进入肿瘤组织以及抗病毒免疫反应。本综述介绍天然及基因修饰溶瘤病毒的不同特征，这些特征有助于其在临床前和临床试验中有效应用，同时总结克服相关限制的策略。溶瘤病毒与其他常规治疗或癌症免疫疗法（包括免疫检查点抑制剂和 CAR-T 治疗）联合，可能成为未来多模式治疗策略的一部分。
展开英文摘要原文
Oncolytic virotherapy is a therapeutic approach that uses replication-competent viruses to kill cancers. The ability of oncolytic viruses to selectively replicate in cancer cells leads to direct cell lysis and induction of anticancer immune response. Like other anticancer therapies, oncolytic virotherapy has several limitations such as viral delivery to the target, penetration into the tumor mass, and antiviral immune responses.
This review provides an insight into the different characteristics of oncolytic viruses (natural and genetically modified) that contribute to effective applications of oncolytic virotherapy in preclinical and clinical trials, and strategies to overcome the limitations. The potential of oncolytic virotherapy combining with other conventional treatments or cancer immunotherapies involving immune checkpoint inhibitors and CAR-T therapy could form part of future multimodality treatment strategies.
论文信息
- 作者
- Abd-Aziz N、Poh CL
- 第一作者单位
- Centre for Virus and Vaccine Research (CVVR), School of Medical and Life Sciences, Sunway University, Subang Jaya, Selangor, Malaysia.Malaysia
- 通讯作者单位
- Centre for Virus and Vaccine Research (CVVR), School of Medical and Life Sciences, Sunway University, Subang Jaya, Selangor, Malaysia. Electronic address: pohcl@sunway.edu.my.Malaysia
- 文献类型
- 非美国政府资助研究 · 综述
- 期刊
- Translational research : the journal of laboratory and clinical medicine2021 Nov
- 原文标识
- PubMed 33905949 · DOI 10.1016/j.trsl.2021.04.008